Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIGF-1 Treatment of Short Stature Associated with Primary IGF-1 Deficiency
2019-001095-11Phase 2
- Sponsor
- Ipsen
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mecasermin in primary insulin-like growth factor 1 deficiency (PIGFD), sponsored by Ipsen. Primary endpoint: Height Velocity.
02
Drugs
mecasermin
03
Conditions
primary insulin-like growth factor 1 deficiency (PIGFD)
Beyond the preview
Go deeper on 2019-001095-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001095-11.